KaydedilenlerDerginizi ekleyin

Dergiler / Diagnostic and Interventional Radiology / 2017 / Cilt: 23 - Sayı: 3

Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary study

Rui WU
Shi-Teng SUO
Lian-Ming WU
Qiu-Ying YAO
Hong-Xia GONG
Jian-Rong XU
Sayfa
245–249
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

WU, R., SUO, S., WU, L., YAO, Q., GONG, H., XU, J. (2017). Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary study. Diagnostic and Interventional Radiology, Cilt: 23 - Sayı: 3, 245–249. https://ajindex.com/articles/193373

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013
  2. 11–30. [CrossRef] 2. Lin C, Luciani A, Itti E, Haioun C, Rahmouni A. Whole body MRI and PET/CT in haematological malignancies. Cancer Imaging 2007
  3. S88–93. 3. Schaefer JF, Schlemmer HP. Total-body MR-imaging in oncology. Eur Radiol 2006
  4. 2000– 2015. [CrossRef] 4. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 2011
  5. 37–43. [CrossRef] 5. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009
  6. 527–533. [CrossRef] 6. MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDGPET. Cancer Imaging 2007
  7. 10–18. [CrossRef] 7. Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 2012
  8. 184–190. [CrossRef] 8. Mikhaeel NG. Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma 2009
  9. 1931–1936. 9. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011
  10. 386–392. [CrossRef] 10. Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011
  11. W384–391. 11. Abdulqadhr G, Molin D, Astrom G, et al. Wholebody diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 2011
  12. 173–180. [CrossRef] 12. Horger M, Claussen C, Kramer U, Fenchel M, Lichy M, Kaufmann S. Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity--a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging. Eur J Radiol 2014
  13. 1655–1664. [CrossRef] 13. Tsuji K, Kishi S, Tsuchida T, et al. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A compari